Acute Myeloid Leukemia (non-APL) · line 1 · CPX-351 (Vyxeos) for tAML / AML-MRC 1L

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-CPX351-AML`

ID	`IND-AML-1L-CPX351-SECONDARY`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-AML`
Sources	`SRC-ELN-AML-2022` `SRC-LANCET-CPX351-2018` `SRC-NCCN-AML-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 1L for SECONDARY AML (tAML, AML-MRC, post-MDS/CMML) age 60-75 fit. Younger fit patients with secondary AML often still get standard 7+3 + risk-adjusted consolidation; CPX-351 specifically positioned for the older subset where fitness is borderline. Ukraine: not registered, dominant access barrier.

Used By

Algorithms

ALGO-AML-1L - ALGO-AML-1L
ALGO-AML-2L - ALGO-AML-2L

Red flag

RF-AML-SECONDARY-AML-MRC-CPX351-ELIGIBLE - AML eligible for CPX-351 (Vyxeos) liposomal cytarabine+daunorubicin per the FDA-approved...